Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Katy J. McCann"'
Autor:
Ben Nicholas, Alistair Bailey, Katy J. McCann, Oliver Wood, Robert C. Walker, Robert Parker, Nicola Ternette, Tim Elliott, Tim J. Underwood, Peter Johnson, Paul Skipp
Publikováno v:
Immunology. 168:420-431
Oesophageal adenocarcinoma (OAC) has a relatively poor long-term survival and limited treatment options. Promising targets for immunotherapy are short peptide neoantigens containing tumour mutations, presented to cytotoxic T-cells by human leucocyte
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64569e110e00231fc6bb451206bb910a
https://doi.org/10.1111/imm.13578
https://doi.org/10.1111/imm.13578
Autor:
Christian H. Ottensmeier, Freda K. Stevenson, Gareth J. Thomas, Ugur Sahin, Petra Simon, Toni Weinschenk, Duncan I. Jodrell, Alan Anthoney, Sally Clive, Ann O'Callaghan, Andrew Bateman, Sarah Halford, Ceri Edwards, Emily Buxton, Paul Lloyd-Evans, Andrew King, Stephen M. Thirdborough, Jana Stasakova, Lindsey Chudley, Angelica Cazaly, Ann Mander, Katy J. McCann
Purpose: We have clinically evaluated a DNA fusion vaccine to target the HLA-A*0201–binding peptide CAP-1 from carcinoembryonic antigen (CEA605–613) linked to an immunostimulatory domain (DOM) from fragment C of tetanus toxin.Experimental Design:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4202489da8884143afe28a39cda33e82
https://doi.org/10.1158/1078-0432.c.6524756.v1
https://doi.org/10.1158/1078-0432.c.6524756.v1
Autor:
Dean Bryant, George E. Wright, James S. Blachly, Jonathan C. Strefford, Graham Packham, Carl G. Figdor, Francesco Forconi, Isla Henderson, Thomas A. Bowden, Giorgia Chiodin, Teunis B. H. Geijtenbeek, Beatriz Valle-Argos, Philip J. Rock, Enrica Antonia Martino, Patrick J. Duriez, Freda K. Stevenson, Yasunori Watanabe, Katy J. McCann, Louis M. Staudt, Max Crispin, Joel D. Allen, Richard Burack
Publikováno v:
Blood, 138(17), 1570-1582. American Society of Hematology
Blood, 138, 17, pp. 1570-1582
Blood, 138, 1570-1582
Blood
Blood, 138, 17, pp. 1570-1582
Blood, 138, 1570-1582
Blood
Glycosylation of the surface immunoglobulin (Ig) variable region is a remarkable follicular lymphoma–associated feature rarely seen in normal B cells. Here, we define a subset of diffuse large B-cell lymphomas (DLBCLs) that acquire N-glycosylation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c29c1bc1823f404e2a7f19678b1ca290
https://hdl.handle.net/2066/244632
https://hdl.handle.net/2066/244632
Autor:
Ben Nicholas, Alistair Bailey, Katy J McCann, Oliver Wood, Robert C Walker, Robert Parker, Nicola Ternette, Tim Elliott, Tim J Underwood, Peter Johnson, Paul Skipp
Esophageal adenocarcinoma (EAC) has a relatively poor long-term survival and limited treatment options. Promising targets for immunotherapy are short peptide neoantigens containing tumor mutations, presented to cytotoxic T-cells by human leukocyte an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61889e2f74dd53f04a3c37ba9e9624cb
https://doi.org/10.1101/2022.05.04.490567
https://doi.org/10.1101/2022.05.04.490567
Autor:
Ferhat Ay, Serena J Chee, Sourya Bhattacharyya, Tilman Sanchez-Elsner, Edwin Woo, Katy J. McCann, Christopher J. Hanley, Christian H. Ottensmeier, Anusha-Preethi Ganesan, Emma King, Aiman Alzetani, Simon Eschweiler, Ravindra Gujar, Bharat Panwar, Oliver Wood, Peter S Friedmann, Gareth J. Thomas, James Clarke, Pandurangan Vijayanand, Ariel Madrigal, Amiera S Awad, Grégory Seumois, Divya Singh
Publikováno v:
The Journal of Experimental Medicine
Clarke et al. interrogate human TRM cells from cancer and nonmalignant tissue. These analyses highlight that PD-1 expression in tumor-infiltrating TRM cells was positively correlated with features suggestive of active proliferation and superior funct
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::deed04325b5dee5a3291fd7f5265d4b6
https://doi.org/10.1084/jem.20190249
https://doi.org/10.1084/jem.20190249
Autor:
Thomas M. Carroll, Joseph A. Chadwick, Richard P. Owen, Michael J. White, Joseph Kaplinsky, Iliana Peneva, Anna Frangou, Jaeho Chang, Phil F. Xie, Andrew Roth, Bob Amess, Hantao Lou, Katy J. McCann, Georgina Berridge, Roman Fischer, Chansavath Phetsouphanh, Ayo O. Omiyale, Brittany-Amber Jacobs, David Ahern, Simon R. Lord, Stewart Norris-Bulpitt, Sam T. Dobbie, Lucinda Griffiths, Kristen Aufiero Ramirez, Toni Ricciardi, Mary J. Macri, Aileen Ryan, Ralph R. Venhaus, Benoit J. Van den Eynde, Ioannis Karydis, Benedikt M. Kessler, Benjamin Schuster-Böckler, Mark R. Middleton, Xin Lu
Publikováno v:
Cancer Research. 82:1247-1247
For patients with inoperable esophageal adenocarcinoma (EAC), prognosis on conventional chemotherapy (CTX) remains poor. In 2021, the FDA approved two αPD-1 immune checkpoint inhibitors (ICI) for addition to fluoropyrimidine/platinum-containing CTX
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76f5d2641b1d59ef3c689eb7850e59cf
https://doi.org/10.1158/1538-7445.am2022-1247
https://doi.org/10.1158/1538-7445.am2022-1247
Autor:
J Thomas, Terry Jones, Pandurangan Vijayanand, James McCaul, Rabindra P. Singh, Allan Hackshaw, Lindsey Chudley, Gareth O. Thomas, Monalisa Mondal, William R. Wilson, Danielle Jeffrey, F. E. Kelly, Christian H. Ottensmeier, Nicola Dobbs, Emma King, Wood Oliver, Yingcong Li, Simon Eschweiler, Louisa Essame, Paul M. Loadman, Joseph E. Davies, Elena Lopez-Guadamillas, Klaus Okkenhaug, Ferhat Ay, Adrian von Witzleben, Joseph J. Sacco, Gavin Halbert, Andrew Schache, Gary Acton, Peter A. Brennan, Claire Paterson, Katy J. McCann, Ciro Ramirez Suastegui, Richard Shaw, Hayley Simon, Alice Wang, Bart Vanhaesebroeck, Greg Friberg
Phosphoinositide 3-kinase δ (PI3Kδ) plays a key role in lymphocytes and inhibitors targeting this PI3K have been approved for hematological malignancies. While studies in hematological and solid tumor models in mice have demonstrated that PI3Kδ in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82bf11ce21becfb1401ec9bfd0cefbc8
https://doi.org/10.21203/rs.3.rs-337290/v1
https://doi.org/10.21203/rs.3.rs-337290/v1
Autor:
Marij J. P. Welters, Dominik Maurer, Ulrik Lassen, Martin Löwer, Bernhard Rossler, Ugur Sahin, Andreas von Deimling, Toni Weinschenk, Christian H. Ottensmeier, Elisa Rusch, Colette Song, Valérie Dutoit, Jordi Rodon, Norbert Hilf, Hans Skovgaard Poulsen, Nina Pawlowski, Francisco Martínez-Ricarte, Judith R. Kroep, Juan Sahuquillo, Claudia Wagner, Edward W. Green, Sonja Dorner, Cedrik M. Britten, Franziska Hoffgaard, Jens Fritsche, Ghazaleh Tabatabai, Stefan Stevanovic, Harpreet Singh-Jasuja, Marco Skardelly, Sabrina Kuttruff-Coqui, Hans-Georg Rammensee, Katharina Kiesel, Alexander Ulges, Carsten Reinhardt, Michael Platten, Alexandra Kemmer-Brück, Bracha Shraibman, Denis Migliorini, Sebastian Kreiter, Jordi Piro, Oliver Schoor, Valesca Bukur, Katrin Frenzel, Berta Ponsati, David Capper, Jorg Ludwig, Monika Stieglbauer, Regina Mendrzyk, Miriam Meyer, Sjoerd H. van der Burg, Evelyna Derhovanessian, Pierre-Yves Dietrich, Arie Admon, Arbel D. Tadmor, Manja Idorn, Wolfgang Wick, Hideho Okada, Per thor Straten, Sandra Heesch, Lukas Bunse, Christoph Huber, Katy J. McCann, Cécile Gouttefangeas, John C. Castle
Publikováno v:
Nature, 565(7738), 240
Nature, Vol. 565, No 7738 (2019) pp. 240-245
Nature, Vol. 565, No 7738 (2019) pp. 240-245
Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors1,2. For treatments using checkpoint inhibitors to be successful, a high mutational load and responses to neo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11b11cf9d2f3e8456103640b3a57a625
https://hdl.handle.net/1887/119498
https://hdl.handle.net/1887/119498
Autor:
Christian H. Ottensmeier, Natalia Savelyeva, Eva Maria Garrido Martin, Matthew J. Ward, Michael S. Breen, Grégory Seumois, Emma King, Christopher H. Woelk, Pandurangan Vijayanand, Katy J. McCann, Terry Jones, Oliver Wood, Lailah Peel, Tilman Sanchez-Elsner, Gareth J. Thomas, Jeongmin Woo, Divya Singh
Publikováno v:
Oncotarget
Human papilloma virus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) has a better prognosis than it's HPV negative (HPV(-)) counterpart. This may be due to the higher numbers of tumor-infiltrating lymphocytes (TILs) in HPV positive (H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::707f7f136e06385b22c2e32001573717
https://pubmed.ncbi.nlm.nih.gov/27462861
https://pubmed.ncbi.nlm.nih.gov/27462861
Autor:
Petra Simon, Paul Lloyd-Evans, Emily Buxton, Stephen M. Thirdborough, Sarah Halford, Angelica Cazaly, Toni Weinschenk, Ann Mander, Jana Stasakova, Christian H. Ottensmeier, Alan Anthoney, Sally Clive, Ann O'Callaghan, Gareth J. Thomas, Andy King, Duncan I. Jodrell, Ceri Edwards, Freda K. Stevenson, Lindsey Chudley, Ugur Sahin, Andrew Bateman, Katy J. McCann
Purpose: We have clinically evaluated a DNA fusion vaccine to target the HLA-A*0201–binding peptide CAP-1 from carcinoembryonic antigen (CEA605–613) linked to an immunostimulatory domain (DOM) from fragment C of tetanus toxin. Experimental Design
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e19df3dd255024ee73f22d958e0fe227